Clinical Research Directory
Browse clinical research sites, groups, and studies.
PRA-216 Atopic Dermatitis Safety and Efficacy Study
Sponsor: Prana Therapies Inc
Summary
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)
Official title: A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Moderate to Severe Atopic Dermatitis
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
39
Start Date
2026-09-01
Completion Date
2027-10-01
Last Updated
2026-09-09
Healthy Volunteers
No
Conditions
Interventions
Active PRA-216
biologic
Placebo
matching placebo for PRA-216
Locations (8)
Emeritus Sydney
Botany, New South Wales, Australia
Cornerstone Centre for Clinical Research
Coorparoo, Queensland, Australia
Emeritus Melbourne
Camberwell, Victoria, Australia
Momentum Sunshine
Melbourne, Victoria, Australia
Optimal Clinical Trials (North)
Auckland, New Zealand
Aotearoa Clinical Trials
Auckland, New Zealand
Momentum Christchurch
Christchurch, New Zealand
Clinical Trials New Zealand
Hamilton, New Zealand